FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Friday

 
HKC Player Multiple Sclerosis
By The Associated Press

HAMILTON, N.Y. (AP) -Mike Campaner, a senior defenseman on the Colgate University hockey team, revealed Thursday that he suffers from multiple sclerosis but has no plans to quit playing the game.

"I feel great and am back to normal health,'' said Campaner, 24. "I want to tell my story because I want to give hope to others who are diagnosed with MS - that they will be able to live a normal life and accomplish any goals that they set for themselves.''

Campaner was diagnosed in November after pulling himself out of a game against Dartmouth.

"I was devastated,'' Campaner said. "I knew it was a crippling disease. Most people end up in a wheelchair. I didn't know what to do.''

MS is an unpredictable disease with no known cure that causes the body's immune system to attack nerve tissue. Scar tissue forms on the nerves, scrambling impulses that control muscles. It can leave people tired and numb, with poor coordination, blurred vision and loss of muscle control. Some have one attack and never experience another, or go years before a second. Others end up becoming more disabled.

Campaner underwent a series of tests and missed nine games while his condition was being evaluated. He is managing his condition through medication and currently is in remission.

"I can't begin to tell you how impressed I have been with how he has handled this situation,'' coach Don Vaughan said. "The first few days after he was diagnosed were frightening times for all of us.''

An ECAC all-rookie team selection in 2004, Campaner finished his collegiate career as one of the most talented defensemen in Colgate history. He scored a career-high 20 points as a junior and completed his career with 62 points in 137 games.

Although he's an undrafted free agent, Campaner plans to pursue a professional career in hockey after graduation. And he has a source of inspiration in Jordan Sigalet of the American Hockey League's Providence Bruins.

Sigalet, a former star at Bowling Green, also has multiple sclerosis. He once couldn't feel how hard he was gripping his stick or squeezing his glove and couldn't even tie the laces on his shoes.

See all stories on this topic: <http://news.google.com/news?hl=en&ncl=http://www.the-dispatch.com/apps/pbcs.dll/article%3FAID%3D/20070329/APS/703292840%26cachetime%3D5>

 

Multiple Sclerosis Society Website - Welcome to the MS Society - Tysabri/Campath

This is the second of the MS Society Awareness Talks available to watch on the internet. This lecture discussed the development of two new drugs for MS - Tysabri and Campath 1-H - and also their effectiveness and problems surrounding them.

You can watch the film of the talk in sections on YouTube, or read the transcript of the lecture together with the slides. You may find it useful to download the relevant slides as they are not always clear on the video.

To make it easier to follow, we separated the transcript for the talk into the following 8 manageable sections:

Part 01 - Introduction
Part 02 - Introduction to Tysabri
Part 03 - Effectiveness of Tysabri
Part 04 - Problems relating to Tysabri
Part 05 - Introduction to Campath-1H
Part 06 - Effectiveness of Campath-1H (Pt.1)
Part 07 - Problems relating to Campath-1H
Part 08 - Effectiveness of Campath-1H (Pt.2)

Labels:


Tuesday

 

Telephone-Based Psychotherapy Shows Durability in Depression - CME Teaching Brief® - MedPage Today

SEATTLE, March 22 -- For depressed patients on medication but too sad to seek psychotherapy as well, lasting help may be available by phone researchers found in a follow-up study.

For more than 75% of nearly 400 patients, the positive effects of six months of brief telephone psychotherapy at the start of antidepressant medication endured for 18 months after the first session, including six months beyond the end of all phone therapy, said Evette Ludman, Ph.D., of the Group Health Cooperative Center for Health Studies here, and colleagues.

This study, reported by Dr. Ludman and colleagues in the April issue of the Journal of Consulting and Clinical Psychology, was a follow-up to a 2004 report on the same sample of 393 patients, published in the Journal of the American Medical Association.

The follow-up found that at 18 months, 77% of those given phone-based therapy reported that depression was "much" or "very much" improved, compared with only 63% of those receiving usual care.

In the 18-month analysis, the benefits of telephone psychotherapy in the first six months were sustained during the second six months when only brief booster sessions were provided. Significantly a "robust clinical benefit" endured for six months after all treatment contact was discontinued, the researchers found.

"As with weight control," Dr. Ludman said, "maintaining improvement is the hardest part of treating depression."

Traditional in-person psychotherapy has limited reach among the large number of patients beginning antidepressant treatment in primary care, the researchers wrote. Expanding access to therapy calls for considering new therapy approaches, such as phone-based sessions, that place greater emphasis on accessibility, outreach, and patient convenience, the investigators concluded.

Of the participants, 195 were randomly assigned to antidepressant medication and usual care while 198 got medication and phone therapy. Of these, 348 (89%) completed the six-month blinded assessment, and 334 (85%) completed the 18-month follow-up.

On average, all patients reported a moderate level of depressive symptoms at baseline, two to four weeks after starting antidepressants prescribed by a primary-care provider.

Phone psychotherapy sessions, delivered by masters-level therapists, included eight core sessions (about 30 minutes) during the first six months, with 15- to 20-minute booster sessions every two months up to a year. After that, phone therapy ended.

According to a structured cognitive behavioral-based psychotherapy program, patients were encouraged to identify and counter their negative thoughts (cognitive behavioral therapy), pursue activities they had enjoyed in the past, and develop a plan to care for themselves....[MORE]


Wednesday

 

Artielle ImmunoTherapeutics Initiates Clinical Trials For Multiple Sclerosis
PORTLAND, Ore. (EWORLDWIRE) Mar 15, 2007

Artielle ImmunoTherapeutics, Inc. today announced that the company has initiated a Phase I clinical trial to evaluate its novel drug candidate, RTL1000, for the treatment of multiple sclerosis (MS). RTL1000 is a novel protein drug with a highly-selective mechanism of action that targets pathogenic T-cells responsible for triggering and sustaining MS.

The trial is currently open for enrollment and is a multi-center, double-blind, placebo controlled, single dose Phase I study to be conducted with 30 MS patients in the United States. The clinical trial is designed to assess the safety and pharmacokinetic properties of RTL1000. The study will be conducted at research centers located in New Haven, Connecticut; Indianapolis, Indiana; Kansas City, Kansas; Baltimore, Maryland; Portland, Oregon and Seattle, Washington. Clinical trial information can be obtained at 'http://www.clinicaltrials.gov/ct/show/NCT00411723' and 'http://www.nationalmssociety.org/Research-trialsrecruiting.asp'.

"The initiation of Phase I clinical trials is an important milestone for Artielle," said Al Ferro, Ph.D., president and CEO of Artielle. "In addition to demonstrating that RTL1000 is safe for human use, this initial trial is designed to provide pharmacokinetic and mechanistic data that will enable us to plan for later-stage clinical trials."

"RTL1000 has demonstrated impressive pre-clinical data in several different disease models and has the potential to add significantly to the clinical options for patients with this disease," said Dennis Bourdette, M.D., chair and Swank professor, department of Neurology, Oregon Health & Science University (OHSU). "There remains a critical unmet need for new therapies for this disease, and I am delighted to be involved with this program." ... [MORE]


Saturday

 
Stem Cell Transplant Doesn't Stop Atrophy in MS: BRAIN Oxford Journals

The present study analyses autopsy material from five multiple sclerosis patients who received autologous stem cell transplantation. A total of 53 white matter lesions were investigated using routine and immunohistochemical stainings to characterize the demyelinating activity, inflammatory infiltrates, acutely damaged axons and macrophages/microglial cells. We found evidence for ongoing active demyelination in all of the five patients. The inflammatory infiltrate within the lesions showed only very few T cells and CD8+ cytotoxic T cells dominated the T cell population. B cells and plasma cells were completely absent from the lesions. High numbers of acutely damaged axons were found in active lesion areas. Tissue injury was associated with activated macrophages/microglial cells. The present results indicate that ongoing demyelination and axonal degeneration exist despite pronounced immunosuppression. Our data parallel results from some of the clinical phase I/II studies showing continued clinical disease progression in multiple sclerosis patients with high expanded disability system scores despite autologous stem cell transplantation.

 
PubMed: Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.

Department of Neurorehabilitation, Royal Berkshire and Battle NHS Trust, Reading, UK. christine.collin@rbbh-tr.nhs.uk

Symptoms relating to spasticity are common in multiple sclerosis (MS) and can be difficult to treat. We have investigated the efficacy, safety and tolerability of a standardized oromucosal whole plant cannabis-based medicine (CBM) containing delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD), upon spasticity in MS. A total of 189 subjects with definite MS and spasticity were randomized to receive daily doses of active preparation (n = 124) or placebo (n = 65) in a double blind study over 6 weeks. The primary endpoint was the change in a daily subject-recorded Numerical Rating Scale of spasticity. Secondary endpoints included a measure of spasticity (Ashworth Score) and a subjective measure of spasm. The primary efficacy analysis on the intention to treat (ITT) population (n = 184) showed the active preparation to be significantly superior (P = 0.048). Secondary efficacy measures were all in favour of active preparation but did not achieve statistical significance. The responder analysis favoured active preparation, 40% of subjects achieved >30% benefit (P = 0.014). Eight withdrawals were attributed to adverse events (AEs); six were on active preparation and two on placebo. We conclude that this CBM may represent a useful new agent for treatment of the symptomatic relief of spasticity in MS.

Thursday

 
This study confirms that brief, moderate, aerobic exercise improves physical fitness in individuals with mild MS

Abstract

This is a randomised control study, to determine the effect of aerobic and strength exercise on physical fitness and quality of life in patients with mild multiple sclerosis (MS). Sixteen outpatients with definitive MS, aged 18-50, with an Expanded Disability Status Scale (EDSS) <4, completed the study. Every patient was evaluated according to physical fitness with peak oxygen consumption (V'O 2peak ), workload and anaerobic threshold; quality of life (SF-36); and degree of disability (EDSS). The patients were then randomised to an exercise group (EG) (n=6) or a control group (CG) (n=10). The EG exercised three times a week for five weeks, and the CG did not change their habits regarding exercise.

In the EG, the mean change in workload was 0.34 W/kg (95% confidence interval (CI): 0.09-0.58), the mean change in V'O 2peak was 4.54 mL/kg per minute (95% CI: 1.65-7.44), and the mean change in anaerobic threshold was 0.32 L/min (95% CI: 0.08-0.57). There was a tendency towards improved quality of life, and no change was detected in the degree of disability. This study confirms that brief, moderate, aerobic exercise improves physical fitness in individuals with mild MS. No evidence was found for worsening of MS symptoms in association with exercises.

 
CME Teaching Brief® - MedPage Today - FDA Warns of Sedative-Aided Sleep Driving and Anaphylaxis

ROCKVILLE, Md., March 14 -- The FDA has taken steps to ensure that clinicians and patients are aware of rare bizarre effects associated with sedative hypnotics, including driving or eating while sleeping.

The agency has ordered makers of all sedative-hypnotic drugs to strengthen label warnings about the risk of "complex sleep-related behaviors" and also severe allergic reactions. The FDA defined sleep driving as "driving while not fully awake after ingestion of a sedative-hypnotic product, with no memory of the event."

Last December, the FDA sent letters to manufacturers of products approved for the treatment of sleep disorders requesting that the whole class of drugs revise product labeling to include warnings about the following potential adverse events:

Anaphylaxis and severe facial angioedema, which can occur the first time the product is taken. Complex sleep-related behaviors which may include sleep-driving, making phone calls, and preparing and eating food while asleep.

"There are a number of prescription sleep aids available that are well-tolerated and effective for many people," said Steven Galson, M.D., MPH, director of FDA's Center for Drug Evaluation and Research. "However, after reviewing the available post-marketing adverse event information for these products, the FDA concluded that labeling changes are necessary to inform health care providers and consumers about risks."

Russell Katz, M.D., director of the FDA's division of neurology products at the center, said the new label will warn that a number of complex-sleep related behaviors "including cooking and eating, using the telephone, having sex, and driving" have been reported by persons using the drugs. Typically, the patient has no memory of these actions.

At a press briefing today, Dr. Katz repeatedly emphasized that the allergic reactions, including anaphylaxis and angioedema, and the complex sleep-related behaviors,"are rare by any definition" and he said the FDA has not received any reports of death associated with either side effect....[MORE]


 

S.A. researcher seeking clues on MS
Don FinleyExpress-News Medical Writer

The biggest question in multiple sclerosis is, why does the body turn on itself and attack the protective insulation around nerves as a dangerous invader?

Short of knowing why, Dr. Thomas Forsthuber is content to figure out how — and better still, how to stop it.

You need a series of unfortunate events to develop the disease, an unfortunate constellation," said Forsthuber, professor of immunology at the University of Texas at San Antonio's South Texas Center for Emerging Infectious Diseases. "We're trying to understand how."

In multiple sclerosis, the body's natural defenses damage and scar the protective myelin sheath — layers of fat and protein — that surrounds nerves, interrupting their signals like a frayed electrical wire. The first symptoms of the disease often are vision problems, followed by muscle weakness, difficulty with coordination and balance, pain and numbness.

Most patients have mild or moderate forms of the disease, with symptoms that come and go, but some are left unable to write, speak or walk. About 400,000 Americans have MS, which is usually diagnosed in people between ages 20 and 40.

Forsthuber brought his work to UTSA a little over a year ago from Case Western Reserve University in Cleveland after 15 years of studying MS and other autoimmune disorders. In August he received his third career research grant from the National Multiple Sclerosis Society to continue his work.

Much about MS remains a mystery. Although people who have a gene known as HLA-DR2 have a higher risk of developing MS, many scientists think some external event — an infection, an injury or a toxic exposure — acts as a trigger.

"This leads to tiny little insult on the brain," he said. "A few cells that surround the myelin sheath die, they release their antigens, the system drains to lymph nodes, and there the immune system comes in touch with them. Then these immune cells do their job. And in this case they're activated against the wrong thing."

This immune system misfiring creates a snowball effect as the body creates more and more immune cells dedicated to identifying and destroying healthy tissue.

Forsthuber's lab has focused on the role of white blood cells known as T lymphocytes, a critical part of the immune system. While the body has hundreds of millions of T cells, each bred to recognize and attack different kinds of foreign invaders, only a select number of rogue T cells target myelin in MS.

Using specially bred mice that have these human HLA genes, the researchers induce a disease similar to MS called experimental autoimmune encephalomyelitis to study how the immune system goes wrong.

By studying the mouse model, researchers have identified bits of myelin protein that might be the target that draws the immune system's wrath.

That has led to a couple of promising avenues for treatment. By slightly altering bits of myelin protein targeted by the immune system, Forsthuber's group has been able to cause those rogue T cells in mice to self-destruct. The next step is to see if — at least in petri dishes — they can do the same thing to rogue human T cells, too.

His lab also is looking at whether tinkering with the immune system in a different way can improve the body's response to steroids, a standard treatment for MS.

"Will we have the cure tomorrow? Probably not, but this is certainly a place where a lot of things are coming together," he said.


 
Newswise - When Your Brain Talks, Your Muscles Don't Always Listen

Newswise — Have your neurons been shouting at your muscles again? It happens, you know.


As we grow older, neurons--the nerve cells that deliver commands from our brains--have to “speak” more loudly to get the attention of our muscles to move, according to University of Delaware researcher Christopher Knight, an assistant professor in UD's College of Health Sciences.


“As a result of age-related changes in muscle and neurons, elderly people are often frustrated by poor control during precision tasks, and slowed physical responses contribute to more falls as people grow older,” Knight said.


Knight and co-author Gary Kamen, who directs the Exercise Neuroscience Laboratory at the University of Massachusetts, recently published the results of a study on motor-unit firing rates in the Journal of Applied Physiology, and Knight is now beginning a new project focusing on motor-control mechanisms in the elderly. Both studies are sponsored by the National Institutes of Health.


The ultimate goal of the research, Knight said, is to improve movement quality in older adults, as well as patients with disorders such as cerebral palsy or multiple sclerosis, or who are recovering from strokes.


Every move you make is made possible through a miraculous communications network involving the brain at the command center, the spinal cord, billions upon billions of nerve cells, and thousands of muscle fibers.


“Muscles are the driving force behind our movements,” Knight said. “Every time they get a command from the neurons, the muscle fibers contract. In the generation of muscular force, the smallest controllable unit consists of an individual neuron and the muscle fibers it stimulates. We believe that our research is very important to our understanding of motor-control mechanisms in general and impaired control in patient populations.”


Shedding light on the communication between neurons and muscles, and how it changes as we age, may lie right at our fingertips, according to Knight's research.


Using an experimental apparatus he and his students created in UD's Human Performance Lab, Knight has been examining muscular force on a very small scale in the index finger, specifically, the first dorsal interosseous muscle. Located between the index finger and the thumb, this muscle contains 120 “motor units”--in other words, 120 individual neurons, or nerve cells, and the muscle fibers they activate.


“It's a relatively simple muscle, so you get to see more of a one-to-one relationship between the activity of the neurons and the resulting muscular force,” Knight said....[MORE]


 

Multiple sclerosis drug brings lethal risks, but great promise for some
By John Fauber
Milwaukee Journal Sentinel

MILWAUKEE - Eric Schmitt munches on a roast beef sandwich as an IV hooked up to his arm drips a precious but potentially lethal fluid into his vein.

Schmitt, 35, knows there is a slight chance the new drug might kill him, but without it his multiple sclerosis could flare up, bringing back the lack of feeling in his lower body, vision problems and difficulty walking.

"I didn't have much choice," he says.

Krista Chapman wakes up worried at 3 a.m. on the day of her first treatment.

After a horrible year of MS relapses in 2006, she reckons that the same drug, Tysabri, will reduce the odds of another setback from which she might not recover, sparing her from disorienting vertigo and overpowering fatigue.

But it also could cause a fatal viral infection in her brain. And at 37, she is too young to die, even though the odds of that seem slim.

As the drug, which costs several thousand dollars a month, slowly is infused into the back of her hand, she seems relaxed sitting up in her hospital bed.

For Schmitt and Chapman as well as an untold number of other MS patients, Tysabri has created a dilemma found with few other medications that treat disabling, but rarely fatal, diseases such as MS...[MORE].

Labels:


 
deseretnews.com - Alpine couple training for MS cure
He'll run marathon 2nd time; she's tackling life with disease

ALPINE — David Roskelley's recipe for running a good marathon could be summed up with three key ingredients: food, family and a firm commitment to going the distance.

Not surprisingly, his wife's secret to living with multiple sclerosis involves the same things.

That's why this Alpine couple will be going back to Boston this April, where David Roskelley will run the Boston Marathon — for the second year in a row — and raise money for the Accelerated Cure Project for Multiple Sclerosis.

"I'm not a super runner, but for me ... it's more about raising funds and awareness and being part of the cause, more than the running aspect," David Roskelley said. "This is a way for me to support my wife and actually do something to show her that I'm supportive of her and trying to help her out."

Lynda Roskelley found out that she has MS, a chronic disorder that affects the central nervous system, in July 2005, about eight months before David decided to run his first Boston Marathon on her behalf.

At that time, the active 36-year-old woman, who ran a 5K in last year's Alpine Days celebration, struggled with the simple task of walking.

"I was going downhill," Lynda Roskelley said. "I couldn't carry my baby up the stairs without (David) walking behind me to make sure I didn't fall over backwards. ... I wouldn't be where I am if he wasn't so supportive in taking a proactive stance and doing everything he can for me."...[MORE]

Tuesday

 
Virtual MS Microscope

BrainMaps.org is an interactive zoomable high-resolution digital brain atlas and virtual microscope that is based on over 15 million megapixels of scanned images of serial sections of both primate and non-primate brains and that is integrated with a high-speed database for querying and retrieving data about brain structure and function over the internet.

You can see an MS brain HERE.

You can also go to this site and click on "multiple sclerosis" under Inflammatory or Infectious Disease.

 
The Enquirer - MS patient writes a play
It's no picnic, but there's also much insight gained in living with this disease
BY PEGGY O'FARRELL

There were plenty of little signs that something was going on. Just fragments, mostly, said Nancy Jones. A little numbness on one side one day. Then, months later, a bout of dizziness. Infections that wouldn't go away.

"They all happened at different times," she said. "They were seemingly unrelated."

Then, in September 1989, she woke up and couldn't see out of her left eye. That was a big sign, Jones said.

A month later, a neurologist put a name to the two years' worth of big and little signs: multiple sclerosis.

Jones was relieved to finally know what was wrong.

She knew multiple sclerosis can be disabling and wondered what she might face one day.

"My best friend's mother died from complications of MS at 45," Jones said. "I watched her go from being a young, active mother with four kids to walking with a cane and then a walker and then being bedridden."

Six people on the street she grew up on in Milford developed multiple sclerosis. "We had our own little cluster," she said.

After living in Cincinnati for many years, Jones moved back to Milford a few years ago because she needed a one-story house... [MORE]

 

Texas hit-maker doesn't let MS slow him down, releases new album.

Texas hit-maker doesn't let MS slow him down, releases new album
More than a decade after being diagnosed with multiple sclerosis, country singer Clay Walker's voice sounds stronger than ever on his first new studio album in four years."Fall," filled with twangy honky tonk songs and ballads that test his range, is set to be released next month.
Walker worked with singer-songwriter/producer Keith Stegall on "Fall," his eighth studio album and his first on Curb Records.
The 37-year-old Walker was diagnosed with MS in 1996 and takes a daily injection of Copaxone to keep the disease in check. MS occurs when patients' immune systems go awry and attack the fatty layer of insulation, called myelin, that protects nerve fibers in the brain and spine, thus damaging or even destroying nerves.
In 2002, Walker started the nonprofit Band Against MS Foundation to raise money for research.
Last week, he presented a check for 100-thousand dollars on behalf of the foundation to the interim dean of the University of Texas Medical School at Houston during a performance at the Houston Livestock Show and Rodeo.

Labels:


 
The Enquirer - Cincinnati team focuses on infection as MS cause
BY PEGGY O'FARRELL

Research under way at the University of Cincinnati could one day help short-circuit the most disabling forms of multiple sclerosis.

Istvan Pirko, a neurologist and researcher in UC's Waddell Center for Multiple Sclerosis, is leading a team of researchers studying the role certain cells in the body's immune system play in the development of multiple sclerosis.

In the disease, the immune system seems to attack myelin, a fatty substance that insulates the nerves. As the insulation is worn away, various symptoms begin, including loss of vision, balance and coordination and muscle weakness and fatigue.

The exact cause of multiple sclerosis is unknown, but some experts believe exposure to environmental toxins or a viral infection might trigger the attack.

Pirko's research focuses on the infection theory. He and his team inject mice with viruses to re-create the symptoms of multiple sclerosis, including tell-tale lesions on the brain.... [MORE]

 

Google Alert - Rebif

Google Alert - Rebif
Sun, 04 Mar 2007 16:29:54 -0800 (PST)
Merck KGaA is delighted as Serono earnings soarPharma Times (subscription) - London,UKFor the full year, Rebif (interferon beta-1a) sales were up 14% to $1.45billion, and up 26% in the USA to $493 million, despite increasingcompetition in ...<MORE>
See all stories on this topic:<HERE>

Labels:


Thursday

 
Scientists in Israel working on feedback systems to improve gait in people with MS recently conducted a trial of a device (PDF) that provides auditory cues to a person while walking. The device is about the size of a cell phone or MP3 player and is connected to headphones that the walker wears. It produces a click each time the walker takes a step, which motivates the walker to keep up a steady gait in order to maintain a pleasingly rhythmic sound.

The trial, which included 14 people with MS and 11 controls, measured walking speed and stride length over four 10-meter lengths before using the device (baseline), while using the device, and again without the device after a rest period. The MS subjects achieved close to a 20% improvement in walking speed and 10% improvement in stride length after this short exercise (controls showed no improvement).

The authors had previously found visual feedback to also be beneficial in walking, and suggest that a therapy combining multiple senses may be worth evaluating for MS and other conditions affecting movement.

 

Chemistry teacher inspired students
Toledo Blade - Toledo, OH, USA

Mrs. Pickut was diagnosed with multiple sclerosis in 1986 while in her 30s, three years after she began teaching at the high school, and a year after the ... <MORE>

See all stories on this topic: <CLICK HERE>


 
Advocacy, Educational Events, and Community Outreach Highlight the Activities Planned by the Multiple Sclerosis Association of America (MSAA) for Multiple Sclerosis Awareness Month
PR Newswire (press release) - New York, NY, USA

MSAA will be hosting various events designed to expand knowledge,understanding, and support of individuals whose lives are affected by multiple sclerosis. ...<MORE>

See all stories on this topic:<CLICK HERE>

 

Rock-It concludes RAMSUM
Maneater Columbia, MO, USA

Phi Mu sorority members perform their act at the Rockin’ Against MultipleSclerosis show Friday night at The Blue Note. RAMS is the largestcampus-wide ...<MORE>

See all stories on this topic:<CLICK HERE>


 
Vaccinex Announces Antibody Development and Commercialization...
PharmaLive.com (press release) - Newtown,PA,USA

VX15 represents a new targeted therapy that has the potential to improve efficacy in treating Multiple Sclerosis (MS) by both suppressing the body's... <MORE>

See all stories on this topic: <CLICK HERE>

 

Teva's multiple sclerosis treatment shows some promise in study.

Teva’s multiple sclerosis treatment shows some promise in study
The Kansas City Star

Copaxone, a multiple sclerosis treatment marketed by Kansas City-based Teva Neuroscience Inc., slowed the progress of the disease in a recent study.....<MORE>

See all stories on this topic:<CLICK HERE>

Labels:


 
BioMS Medical initiates follow-on open-label MAESTRO-02 Multiple Sclerosis trial of MBP8298
Canada NewsWire (press release)

A phase II trial evaluating MBP8298 for the treatment of relapsing remitting multiple sclerosis (RRMS). The trial is a randomized,double-blind...<MORE>

See all stories on this topic: <CLICK HERE>


Go to Newer News Go to Older News